Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 20/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 20/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 19/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 19/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18705654 | 0.83 | CHRNB2 (0.62) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL19948600 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1404444 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL5965871 | 0.79 | CHRNB2 (0.59) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL30259987 | 0.77 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1588528 | 0.77 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL7006653 | 0.77 | CHRNB2 (0.57) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL30260009 | 0.77 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25391666 | 0.76 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL5773702 | 0.76 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023056951-A1 | ARYL-SUBSTITUTED HETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2023-04-13 | — | — | WO | disclosed |